Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52-week, open-label study

Journal of Diabetes Investigation

Volumn 7, Issue 1, 2016, Pages 100-108

  Yasuda, Hitoshi ^a   Hotta, Nigishi ^b   Kasuga, Masato ^c   Kashiwagi, Atsunori ^d   Kawamori, Ryuzo ^e   Yamada, Tadaaki ^f   Baba, Yuko ^f   Alev, Levent ^g   Nakajo, Ko ^g  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b CHUBU ROSAI HOSPITAL   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d Kusatsu General Hospital   (Japan)

^e JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f SHIONOGI AND CO LTD   (Japan)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

Diabetes related complications; Diabetic neuropathy (painful); Duloxetine

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; DULOXETINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; PLACEBO;

ADULT; ARTICLE; BODY WEIGHT; BRAIN INFARCTION; BRIEF PAIN INVENTORY; CLAVICLE FRACTURE; CLINICAL GLOBAL IMPRESSION SCALE; COLON CANCER; COMPRESSION FRACTURE; CONSTIPATION; CONTROLLED STUDY; DIABETIC NEUROPATHIC PAIN; DIABETIC NEUROPATHY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENERALIZED EDEMA; HEART FAILURE; HEART RATE; HUMAN; HYPOGLYCEMIA; JAPANESE (PEOPLE); LEUKOCYTE COUNT; LONG TERM CARE; LUNG INJURY; LYMPHOMA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHIC PAIN; OPEN STUDY; PNEUMOTHORAX; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SOMNOLENCE; SPINE FRACTURE; STOMACH CANCER; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETIC NEUROPATHIES; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; JAPAN; MIDDLE AGED; PAIN MEASUREMENT; PROCEDURES; TIME FACTOR;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETIC NEUROPATHIES; DISORDERS OF EXCESSIVE SOMNOLENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DULOXETINE HYDROCHLORIDE; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NAUSEA; PAIN MEASUREMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84956708447     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12361     Document Type: Article

References (33)

1. Barrett AM, Lucero MA, Le T, et al. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 2007; 8(Suppl 2): S50-S62.
2. Chan JC, Chan SP, Deerochanawong C, et al. Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: what we know and don't know. Diabetes Res Clin Pract 2011; 94: 1-13.
3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
4. Hanaoka K, Ogawa S, Hotta N, et al. Current status of neuropathic pain treatment in Japan and scope in future - proposal from the consensus conference of specialists. Pain Clinic 2009; 30: 1395-1408 (Japanese).
5. Sadosky A, McDermott AM, Brandenburg NA, et al. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract 2008; 8: 45-56.
6. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962.
7. Gore M, Brandenburg NA, Dukes E, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005; 30: 374-385.
8. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007; 68: 1178-1182.
9. Zelman DC, Brandenburg NA, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain 2006; 22: 681-685.
10. Tesfaye S. Recent advances in the management of diabetic distal symmetrical polyneuropathy. J Diabetes Investig 2011; 2: 33-42.
11. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 2011; 27: 629-638.
12. Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997; 59: 241-250.
13. Ray WA, Meredith S, Thapa PB, et al. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004; 75: 234-241.
14. Zimmermann U, Kraus T, Himmerich H, et al. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003; 37: 193-220.
15. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871-880.
16. Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 2012; 35: 2451-2458.
17. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109-118.
18. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6: 346-356.
19. Skljarevski V, Frakes EP, Sagman D, et al. Review of efficacy and safety of duloxetine 40 to 60 mg once daily in patients with diabetic peripheral neuropathic pain. Pain Res Treat 2012; 2012: 898347.
20. Tanenberg RJ, Irving GA, Risser RC, et al. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc 2011; 86: 615-626.
21. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67: 1411-1420.
22. Yasuda H, Hotta N, Nakao K, et al. Superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in Japan. J Diabetes Investig 2011; 2: 132-138.
23. Wernicke JF, Wang F, Pritchett YL, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med 2007; 8: 503-513.
24. Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med 2006; 9: 29-40.
25. Hall JA, Wang F, Oakes TM, et al. Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials. Expert Opin Drug Saf 2010; 9: 525-537.
26. Diabetic Neuropathy Study Group. Abbreviated diagnostic criteria for distal symmetric polyneuropathy. Peripher Nerv 2003; 14: 225 (Japanese).
27. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore 1994; 23: 129-138.
28. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare Publication, National Institute of Mental Health, Rockville, 1976; 129-138.
29. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig 2012; 3: 39-40.
30. Raskin J, Wang F, Pritchett YL, et al. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 2006; 7: 373-385.
31. National Institute for Health and Clinical Excellence (NICE). Short Clinical Guideline 87. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0033486/. Effective May 2009. Accessed 13 March 2013.
32. Hardy T, Sachson R, Shen S, et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007; 30: 21-26.
33. Wasan AD, Ossanna MJ, Raskin J, et al. Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients. Curr Drug Saf 2009; 4: 22-29.